Ulotaront

Small molecule

Also known as SEP-363856

Negativelead readout

Evidence outlook · lead readout

NCT04092686 · Schizophrenia

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.

NCT04092686: This was a randomized, quadruple-masked, placebo-controlled trial with 464 participants and a clinical symptom-score primary endpoint (PANSS). The sponsors report that neither ulotaront dose was statistically better than placebo on the primary endpoint. The 100 mg arm separated from placebo nominally, and the registry lists an adjusted one-sided p of 0.041 for it after Hochberg gatekeeping, but the sponsors do not report this as a significant result.

Also in development:Generalized Anxiety Disorder · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (12)
Generalized Anxiety Disorder
NCT07786454 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-10-08 – 2029-06-02 · Generalized Anxiety Disorder
What this study did
NCT07759128 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-07-28 – 2028-12-13 · Generalized Anxiety Disorder
What this study did
NCT07767903 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-08-06 – 2028-11-01 · Generalized Anxiety Disorder
What this study did
Schizophrenia
NCT07225712 · Otsuka Pharmaceutical Co., Ltd.
2025-12-22 – 2028-03 · Schizophrenia
What this study did
NCT06894212 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2025-02-28 – 2026-10-29 · Schizophrenia
What this study did
NCT05359081 · Sumitomo Pharma Co., Ltd.
2022-05-16 – 2024-03-28 · Schizophrenia
What this study did
NCT04109950 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-11-20 – 2023-11-09 · Schizophrenia
What this study did
NCT04115319 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-11-21 – 2022-12-30 · Schizophrenia
What this study did
Phase 2/3 (2)
Generalized Anxiety Disorder
Schizophrenia
NCT04825860 · Sumitomo Pharma Co., Ltd.
2021-03-29 – 2023-10-19 · Schizophrenia
What this study did
Phase 2 (4)
Schizophrenia
NCT02970929 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2017-01-31 – 2019-01-29 · Schizophrenia
What this study did
NCT02969382 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2016-12-05 – 2018-07-31 · Schizophrenia
What this study did
Other / comorbidity
NCT05593029 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-09 – 2025-11-13 · Major Depressive Disorder
What this study did
NCT02969369 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2016-12-31 – 2020-04-20 · Parkinson Disease Psychosis
What this study did
Phase 1 (13)
Schizophrenia
NCT05848700 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2023-06-21 – 2024-03-15 · Schizophrenia
What this study did
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
NCT05463770 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-08-30 – 2023-08-22 · Schizophrenia
What this study did
NCT04038957 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-08-07 – 2023-06-06 · Schizophrenia
What this study did
NCT04865835 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2021-05-12 – 2022-05-03 · Schizophrenia
What this study did
NCT04369391 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2020-06-18 – 2020-11-10 · Schizophrenia
What this study did
NCT04325737 · Sumitomo Pharma Co., Ltd.
2020-03-31 – 2020-08-07 · Schizophrenia
What this study did
NCT03370640 · Sumitomo Pharma Co., Ltd.
2017-11-29 – 2018-09-20 · Schizophrenia
What this study did
NCT01972711 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-03 – 2015-07 · Schizophrenia
What this study did
NCT01994473 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-10 – 2014-12 · Schizophrenia
What this study did
NCT01940159 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-08 – 2014-03 · Schizophrenia
What this study did
Other / comorbidity

Competitive landscape

This drug's own stage for Generalized Anxiety Disorder: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ulotaront: this drugPhase 3Small moleculeTAAR1 (trace amine-associated receptor 1)not yet gradedNo reviewed efficacy summary in this indication
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
DeulumateperonePhase 3Small moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 3Small molecule5-HT2A receptorPartial signal
NCT06809595: Primary endpoint, HAM-A change at week 12 (100 µg): -9.8 vs -4.7 with placebo, LS mean difference -5.1 points (p<0.0001) (Definium, 2026-09-14).
NCT06741228: Primary endpoint, HAM-A change: -11.6 vs -6.2 with placebo, LS mean difference -5.4 points (p<0.0001) (Definium, 2026-08-12).

Upcoming events

(4 total)

Covered in the briefing Q4 2026 readouts that matter.

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ulotaront to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (3)
March 2028 (1)
Phase 3SchizophreniaRecruiting
Est. primary completion 2028-03 · NCT07225712 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Generalized Anxiety DisorderRecruiting
Est. primary completion 2028-10-25 · NCT07767903 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Generalized Anxiety DisorderRecruiting
Est. primary completion 2028-12-06 · NCT07759128 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 3Generalized Anxiety DisorderRecruiting
Est. primary completion 2029-05-26 · NCT07786454 · CT.gov ↗
What to watch

See the full readout calendar ↗